XML 24 R9.htm IDEA: XBRL DOCUMENT
v3.22.1

Invitae Collaboration | 3 Months Ended
--- | ---
Mar. 31, 2022
Invitate Collaboration [Abstract] |
Invitae Collaboration | NOTE 3. INVITAE COLLABORATIO N On January 12, 2021 we entered into a multi-year Development and Commercialization Agreement (the “Development Agreement”) with Invitae Corporation (“Invitae”). Pursuant to the Development Agreement, Invitae is providing certain funding to us to develop products relating to production-scale high-throughput sequencing (“Program Products”). If Program Products become commercially available, Invitae may purchase the Program Products. We are currently renegotiating the terms of the Development Agreement. As of March 31, 2022 and December 31, 2021, we have recognized payments received from Invitae of $23.5 million in deferred revenue, non-current, on the Consolidated Balance Sheet.

X
- Definition Development and Commercialization Of Significant Agreements Disclosure [Text Block] + References No definition available. + Details
Name: | pacb_DevelopmentAndCommercializationOfSignificantAgreementsDisclosureTextBlock
Namespace Prefix: | pacb_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development and Commercialization Of Significant Agreements [Abstract] + References No definition available. + Details
Name: | pacb_SignificantAgreementsAbstract
Namespace Prefix: | pacb_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration